SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

ARO-ALK7

ARWR·ARROWHEAD PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1/2a
Time to market
Assuming successful clinical development, ARO-ALK7 is likely 5+ years away from potential approval, as it is still in early Phase 1/2a with no pivotal trial initiated.
Why 3/10
ARO-ALK7 is an early Phase 1/2a asset with no scheduled PDUFA, pivotal readout, or other hard dated binary catalyst within the next ~12 months. The next catalyst would be additional interim clinical data, but no specific date has been announced. As one program among several at a multi-pipeline company, it represents a small portion of Arrowhead's overall valuation.
Actionable Insight NEUTRAL

Watch for additional interim data from the Phase 1/2a AROALK7-1001 study, which could come at future medical meetings or investor events. The Roche-Rona ALK7 deal (up to $1.16B) validated the target in October 2026, reducing Arrowhead's technical risk. However, ARO-ALK7 remains an early-stage program within a diversified pipeline; ARWR's nearer-term catalysts are plozasiran, ARO-DIMER-PA, ARO-MAPT, and ARO-INHBE data.

Price Chart

Loading chart...

Executive Summary

ARO-ALK7 is Arrowhead Pharmaceuticals' second RNAi-based obesity candidate, targeting Activin receptor-like kinase 7 (ALK7) in adipose tissue to promote fat breakdown. It entered Phase 1/2a clinical testing (AROALK7-1001) in mid-2025, and interim data from January 2026 showed it is the first RNAi therapeutic to demonstrate adipocyte gene target silencing in humans, achieving mean ALK7 mRNA reductions of 88% at the 200 mg dose. The obesity drug space is intensely competitive, but the October 2026 Roche-Rona Therapeutics ALK7 licensing deal (up to $1.16 billion) provided significant external validation of the target. However, ARO-ALK7 remains an early-stage program within Arrowhead's broader pipeline, with no near-term binary catalyst on the calendar.

How It Works

ARO-ALK7 is an RNA interference (RNAi) therapeutic that silences the gene for Activin receptor-like kinase 7 (ALK7) in fat (adipose) tissue. ALK7 is a receptor that normally tells fat cells to stop breaking down stored fat. By turning off ALK7, the drug aims to increase fat breakdown and reduce fat mass, potentially leading to weight loss while preserving lean muscle. It uses a small interfering RNA (siRNA) molecule delivered to fat cells.

Trial Status

ARO-ALK7 is being evaluated in a Phase 1/2a clinical trial (AROALK7-1001). The first patient was dosed in June 2025. Interim data released in January 2026 showed target engagement with dose-dependent ALK7 mRNA silencing in adipose tissue (mean 88% reduction at 200 mg). Additional interim data from the ongoing study are expected but no specific date has been announced.

The Two-Sided Case

▲ Bull Case5
A January 2026 interim readout showed ARO-ALK7 is the first RNAi therapeutic to achieve adipocyte gene target silencing, with mean ALK7 mRNA reductions of -88% at the 200 mg dose at week 8 and maximum of -94% (n=4).
Roche licensed an ALK7-targeting RNAi from Rona Therapeutics in October 2026 for up to $1.16 billion, providing strong external validation of the ALK7 target in obesity.
ARO-ALK7 targets a novel mechanism (blocking ALK7 signaling that suppresses fat breakdown) that could preserve lean muscle mass better than GLP-1 agonists.
Arrowhead has a broad RNAi platform with deep expertise in extrahepatic delivery, and ARO-ALK7's ability to target adipose tissue demonstrates platform progress.
Analyst consensus is strong buy (20 analysts: 7 strong buy, 13 buy, 1 hold) with a mean price target of $106.07 (122% upside from $47.78).
▼ Bear Case5
ARO-ALK7 is early stage (Phase 1/2a) with no pivotal or registrational data; clinical failure could wipe out its value.
The obesity market is intensely competitive, with GLP-1 drugs from Novo Nordisk and Eli Lilly dominating, plus numerous other mechanisms in development.
Arrowhead's stock has fallen from a 52-week high of $95.49 to $47.78 as of November 13, 2026, reflecting significant share price decline.
Insider sales in August 2026 at ~$87/share and significant institutional trims/exits in Q3 2026 (First Trust, 1832 Asset Management, HRT Financial, Renaissance Technologies) suggest near-term skepticism.
The Roche-Rona ALK7 deal creates a potential competitor with Big Pharma backing.

Upcoming Catalysts

  • Additional interim Phase 1/2a data from AROALK7-1001 (no date specified)
  • Potential investor day or conference presentation of updated data
  • Initiation of Phase 2 studies (timeline uncertain)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report

Sources · 7

Hover a chip for the title
1 businesswire.com2 nasdaq.com3 nasdaq.com4 nasdaq.com5 bioworld.com6 prnewswire.com7 businesswire.com